Summary
The AI response appears to discuss patent and exclusivity claims that are not part of the FDA-approved labeling for Tagrisso; label content (safety, dosing, pregnancy, pediatric use, and boxed warnings) is not addressed by the provided claims, and the patent-focused claims are not present in the labeling.
Category Scores
Accurate Statements
Unsupported Statements
Tagrisso (osimertinib) core composition patent WO 2013/095341 covers the composition‑of‑matter (core drug).
US expiry for core composition patent WO 2013/095341 is 2032-07-28.
EU expiry for core composition patent WO 2013/095341 is 2033-05-13.
WO 2014/042058 covers pharmaceutical formulation & dosing for osimertinib.
US expiry for formulation patent WO 2014/042058 is 2028-08-14.
EU expiry for formulation patent WO 2014/042058 is 2029-02-08.
WO 2015/023241 covers stereochemical purity & synthesis for osimertinib.
US expiry for stereochemistry patent WO 2015/023241 is 2035-04-15.
EU expiry for stereochemistry patent WO 2015/023241 is 2035-01-15.
US 9,549,423 covers analytical testing & quality control methods for osimertinib.
US expiry for US 9,549,423 is 2039-03-04.
US 10,123,456 covers packaging & labeling for osimertinib products.
US expiry for US 10,123,456 is 2036-05-10.
EU expiry for US 10,123,456 is 2037-05-10.
European Patent EP 3 123 456 expiry is 2033-07-20; notes: same as WO 2013/095341.
Core composition patents WO 2013/095341 / US 8,597,037 run until US 2032 and EU 2033.
Formulation/Manufacturing patents expire earlier (2028-2029) and are typically the first to be challenged by generics.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Patent/exclusivity content not part of FDA labeling; misalignment due to inclusion of non-label information.
Suggested Improvement
Limit outputs to information present in FDA labeling; exclude patent and exclusivity claims when evaluating label alignment; if patent terms are relevant, separate regulatory documentation should be consulted.